Navigation Links
ChanTest Develops New Cardiotoxicity and Contractility Assay with Human Stem Cell Cardiomyocytes
Date:5/14/2013

Cleveland, OH (PRWEB) May 14, 2013

Cardiovascular (CV) toxicity is a leading contributor to drug withdrawal and late-stage attrition in the drug discovery process. There is an urgent need for novel in vitro assays that enable earlier and broader testing for CV activity.

The most relevant cells for pre-clinical testing are human cells. Use of these cells has the potential to add significant efficiencies, reduce animal use and decrease the number of dangerous drugs that reach the market.

In response to this need, ChanTest has developed a new assay using ACEA Bioscience’s xCELLigence System (San Diego, CA) and human induced pluripotent stem cell (iPSC) derived cardiomyocytes from Cellular Dynamics International (CDI, Madison, WI). Based on an extensive research program, ChanTest has created several unique algorithms for twitch detection and kinetic analysis, and has concluded an investigation that suggests twitch impedance is a sensitive tool to assess contraction in a relatively high-throughput assay.

The studies concluded that the impedance twitch recordings accurately reflect key elements of contraction, thus allowing the study of drugs that affect excitation-contraction coupling and the contractile apparatus. In addition, since impedance signals can be recorded over long periods of time, deleterious long-term drug effects, such as those commonly observed for oncology drugs, can be easily evaluated with this label-free procedure. Therefore, the new ChanTest assay, applied to iPSC derived cardiomyocytes, offers an effective non-invasive screen for the cardiotoxicity and contractility.

"We listened to the requests of the pharmaceutical industry for a human cell based cardiotox and contractility assay," explained Chris Mathes, Ph.D., Chief Commercial Officer at ChanTest. "This new assay fulfills that need by combining ChanTest expertise with state-of-the art technology from ACEA and iPSC cardiomyocytes from CDI."

To learn more about the new ChanTest assay using ACEA Bioscience’s xCELLigence system, click here.

FURTHER INFORMATION

ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and nonclinical cardiac risk assessment service portfolio is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past eight years. ChanTest is based in Cleveland, Ohio.

Visit http://www.chantest.com to learn more about what we do.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10724621.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
2. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
3. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
4. NASA develops super-black material that absorbs light across multiple wavelength bands
5. UCLA team develops highly efficient method for creating flexible, transparent electrodes
6. Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products
7. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
8. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
9. College Chairman And Prolific Inventor Develops Life-Saving, Real-Time Diagnostic Technologies
10. Union Equity, Inc.s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy
11. Medi-Solve Coatings Develops Masking Process for Medical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... quality, regulatory and technical consulting, provides a free webinar on Performing ... July 13, 2016 at 12pm CT at no charge. , Incomplete investigations are ...
(Date:6/23/2016)... ReportsnReports.com adds 2016 global ... pharmaceuticals section with historic and forecast data along ... Complete report on the Cell Culture ... companies and supported with 261 tables and figures ... The Global Cell Culture Media Industry ...
(Date:6/22/2016)... , June 22, 2016  According to Kalorama ... generation sequencing (NGS) market include significant efforts in ... sequencers.  More accessible and affordable sequencers, say the ... demand for consumables including sample prep materials.  The ... for Sample Preparation for Next Generation Sequencing (NGS) ...
(Date:6/22/2016)...   ViaCyte, Inc. , a privately-held regenerative medicine ... therapy for the treatment of diabetes in clinical-stage development, ... ISSCR 2016, the Global Stem Cell Event, is taking ... San Francisco.    ... , Focus Session: Tools for Basic and Applied Stem ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):